-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
MiNK Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2020 to Q2 2024.
- MiNK Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$3.07M, a 51.6% increase year-over-year.
- MiNK Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$17.6M, a 37.2% increase year-over-year.
- MiNK Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$22.9M, a 25.9% increase from 2022.
- MiNK Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$30.9M, a 9.14% decline from 2021.
- MiNK Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$28.4M, a 93.7% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)